ClinicalTrials.gg
CompletedNCT06506994Updated Nov 17, 2025

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

A Phase 1 interventional study of HRS-9057 and HRS-9057 in Heart Failure With Volume Overload, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, none of them phase 3. Heart Failure · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
9th of 10
25 · median 69
Started
2024
with 1 other
Phase 1
6 of 10
3 open now
Registered
3rd of 10
by date

Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 3rd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is an open-label, Tolvaptan-controlled Phase I study to evaluate the safety, tolerability, PK/PD profile and efficacy of HRS-9057 in the treatment of heart failure with volume overload. A total of 24 subjects who experience volume overload due to heart failure despite diuretic treatment will be enrolled in the study and receive HRS-9057 injection or Tolvaptan tablets.

03

Conditions studied

  • Heart Failure With Volume Overload

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age 18-75 years at the time of signing .
  2. Diagnosed as chronic heart failure at least 1 month prior to screening.
  3. Patients with CHF in whom lower limb edema, pulmonary congestion, jugular venous distension or hepatomegaly due to volume overload is present despite diuretics treatment.

Exclusion criteria

Exclusion Criteria:

  1. Medical history of myocardial infarction, acute decompensated heart failure, stroke, or within 30 days prior to or at screening;
  2. Hypovolemic hyponatremia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS-9057/ Tolvaptan

    Drug: HRS-9057 · Drug: Tolvaptan

  • Experimental
    Treatment group B: HRS-9057/ Tolvaptan

    Drug: HRS-9057 · Drug: Tolvaptan

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence and severity of any adverse events (AEs)

    Time frame: baseline up to Day 14

Secondary outcomes

  1. Tmax for HRS-9057

    Time frame: Predose on Day 1 through Day 6

  2. Cmax for HRS-9057

    Time frame: Predose on Day 1 through Day 6

  3. Daily urine volume

    Time frame: Predose on Day 1 through Day 7

  4. Daily fluid balance

    Daily fluid balance is calculated by subtracting daily urine volume from daily fluid intake.

    Time frame: Predose on Day 1 through Day 7

  5. Serum sodium concentration

    Time frame: Predose on Day 1 through Day 6

  6. Serum osmolality

    Time frame: Predose on Day 1 through Day 6

  7. Urine osmolality

    Time frame: Predose on Day 1 through Day 7

  8. Body weight

    Time frame: baseline to Day 8

  9. Lower limb edema change from baseline

    The severity of edema in the subject's tibial border or dorsum of the foot will be assessed in the sitting position using a 4-point scale (0-absent, 1-mild, 2-moderate and 3-severe) by the investigator. The percentage of subjects in whom the lower limb edema was improved or worsening at Day 8 will be evaluated.

    Time frame: baseline to Day 8

  10. Jugular venous distension change from baseline

    Whether or not the subject has jugular venous distension will be documented. If distension is observed, the vertical height (in centimeters) from the sternal angle to the highest point of pulsation of the internal jugular vein will be documented and the change from baseline to Day 8 will be evaluated.

    Time frame: baseline to Day 8

  11. Pulmonary congestion change from baseline

    The investigator will perform chest X-ray at baseline and Day 8 to assess the severity of pulmonary congestion using a 4-point scale (0-absent, 1-mild, 2-moderate and 3-severe). The percentage of subjects in whom pulmonary congestion was improved or worsening at Day 8 will be evaluated.

    Time frame: baseline to Day 8

  12. New York Heart Association (NYHA) classification change from baseline

    Time frame: baseline to Day 8

07

Study locations

1 site
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510285, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2025, 14 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 18, 2024
StartActual
Aug 16, 2024
Primary completionActual
Oct 29, 2025
CompletionActual
Oct 29, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06506994
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Aug 16, 2024
Primary completion
Oct 29, 2025
Completion
Oct 29, 2025
Last update
Nov 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9057

Start the discussion